Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease
- PMID: 1332484
- PMCID: PMC1886657
Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease
Abstract
A chimeric model consisting of severe combined immune deficiency (SCID) mice populated with human peripheral blood leukocytes (PBL) has recently been described (bu-PBL-SCID mice). These reports indicated a limited reconstruction of the transferred human immune system and functionality of the human graft. Herein we described modifications of the PBL transfer method that minimize transfer time and cellular manipulations, leading to a more effective population of SCID mouse recipients. Severe combined immune deficiency mice given 15 x 10(6) PBL had human IgG serum levels reaching 2 to 5 g/l, and all mice had detectable human anti-tetanus toxoid antibody levels when they received cells from donors with such levels. These transfers were associated also with clinical and histologic evidence of graft-versus-host disease, suggesting responsiveness of the human graft in the recipients. When Epstein-Barr virus seropositive (EBV+) donors were used, the chimeric mice also showed a high incidence of fatal lymphoproliferative disease 1 to 3 months after transfer of 15 x 10(6) PBL. The high level of immunoglobulin synthesis and immunoresponsiveness of the human cells with this transfer procedure may expand the use of these chimeric mice for the manipulations of human immune cells in vivo.
Similar articles
-
The hu-PBL-SCID mouse model. Long-term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice.Cell Immunol. 1992 Feb;139(2):468-77. doi: 10.1016/0008-8749(92)90086-5. Cell Immunol. 1992. PMID: 1733515
-
A model of human anti-T-cell monoclonal antibody therapy in SCID mice engrafted with human peripheral blood lymphocytes.Clin Transplant. 1997 Oct;11(5 Pt 2):522-8. Clin Transplant. 1997. PMID: 9361954
-
Anti-tetanus toxoid antibody production and protection against lethal doses of tetanus toxin in hu-PBL-SCID mice.Int Arch Allergy Immunol. 2000 Oct;123(2):149-54. doi: 10.1159/000024434. Int Arch Allergy Immunol. 2000. PMID: 11060487
-
Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer.Cancer J Sci Am. 1997 Dec;3 Suppl 1:S129-36. Cancer J Sci Am. 1997. PMID: 9457408 Review.
-
EBV-induced human B cell lymphomas in hu-PBL-SCID mice.AIDS Res Hum Retroviruses. 1992 May;8(5):735-40. AIDS Res Hum Retroviruses. 1992. PMID: 1325170 Review.
Cited by
-
Humanized Mice as Unique Tools for Human-Specific Studies.Arch Immunol Ther Exp (Warsz). 2018 Aug;66(4):245-266. doi: 10.1007/s00005-018-0506-x. Epub 2018 Feb 7. Arch Immunol Ther Exp (Warsz). 2018. PMID: 29411049 Free PMC article. Review.
-
Advances in Transgenic Mouse Models to Study Infections by Human Pathogenic Viruses.Int J Mol Sci. 2020 Dec 5;21(23):9289. doi: 10.3390/ijms21239289. Int J Mol Sci. 2020. PMID: 33291453 Free PMC article. Review.
-
Humanized Mice for Studies of HIV-1 Persistence and Elimination.Pathogens. 2023 Jun 27;12(7):879. doi: 10.3390/pathogens12070879. Pathogens. 2023. PMID: 37513726 Free PMC article. Review.
-
The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice.Sci Rep. 2015 Mar 30;5:9447. doi: 10.1038/srep09447. Sci Rep. 2015. PMID: 25819560 Free PMC article.
-
SCID mice in the study of human autoimmune diseases.Springer Semin Immunopathol. 1992;14(2):159-77. doi: 10.1007/BF00195292. Springer Semin Immunopathol. 1992. PMID: 1475742 Review. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources